$18.42
1.13%
Nasdaq, Nov 28, 10:00 pm CET
ISIN
US45257U1088
Symbol
IMNM

Immunome Inc Stock price

$18.42
+2.03 12.39% 1M
+9.79 113.44% 6M
+7.80 73.45% YTD
+4.95 36.75% 1Y
+14.92 426.29% 3Y
+7.22 64.46% 5Y
+4.97 36.95% 10Y
+4.97 36.95% 20Y
Nasdaq, Closing price Fri, Nov 28 2025
-0.21 1.13%
ISIN
US45257U1088
Symbol
IMNM
Industry

Key metrics

Basic
Market capitalization
$1.7b
Enterprise Value
$1.4b
Net debt
positive
Cash
$272.6m
Shares outstanding
91.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
174.5 | 219.8
EV/Sales
146.4 | 184.3
EV/FCF
negative
P/B
6.4
Financial Health
Equity Ratio
75.4%
Return on Equity
-161.7%
ROCE
-77.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$9.7m | $7.7m
EBITDA
$-205.0m | $-202.0m
EBIT
$-206.9m | $-200.9m
Net Income
$-222.7m | $-200.3m
Free Cash Flow
$-198.3m
Growth (TTM | estimate)
Revenue
-4.4% | -15.0%
EBITDA
-86.2% | -33.0%
EBIT
-85.2% | -30.9%
Net Income
27.1% | 31.6%
Free Cash Flow
-43.0%
Margin (TTM | estimate)
Gross
-
EBITDA
-2,117.5% | -2,627.6%
EBIT
-2,137.1%
Net
-2,301.3% | -2,606.3%
Free Cash Flow
-2,049.1%
More
EPS
$-2.5
FCF per Share
$-2.2
Short interest
16.3%
Employees
155
Rev per Employee
$60.0k
Show more

Is Immunome Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

Immunome Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Immunome Inc forecast:

17x Buy
94%
1x Hold
6%

Analyst Opinions

18 Analysts have issued a Immunome Inc forecast:

Buy
94%
Hold
6%

Financial data from Immunome Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
9.68 9.68
4% 4%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 42 42
37% 37%
435%
- Research and Development Expense 174 174
91% 91%
1,802%
-205 -205
86% 86%
-2,117%
- Depreciation and Amortization 1.90 1.90
15% 15%
20%
EBIT (Operating Income) EBIT -207 -207
85% 85%
-2,137%
Net Profit -223 -223
27% 27%
-2,301%

In millions USD.

Don't miss a Thing! We will send you all news about Immunome Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immunome Inc Stock News

Neutral
Business Wire
6 days ago
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members of Immunome's management will participate in the following investor conferences: Piper Sandler 37th Annual Healthcare Conference Presentation Date/Time: December 3, 2025, at 9 a.m. ET 8th Annual Eve...
Neutral
Business Wire
25 days ago
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended September 30, 2025, and provided a business update. “Immunome's pipeline continues to advance,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Immun...
Neutral
Business Wire
27 days ago
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on Nov. 3, 2025, the Compensation Committee of the company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase ...
More Immunome Inc News

Company Profile

Immunome, Inc. operates as a transformative immuno-oncology company. It creates new, safe, and powerful cancer therapies by targeting stem cell and universal cancer antigens. The firm offers discovery engine that enables the simultaneous discovery of novel tumor antigens and the cognate native human antibodies that target those antigens. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Exton, PA.

Head office United States
CEO Clay Siegall
Employees 155
Founded 2006
Website immunome.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today